套细胞淋巴瘤-话题@MedSci

#套细胞淋巴瘤#

9篇内容 | 1326人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2198390, encodeId=e00e2198390b7, content=<a href='/topic/show?id=56b0194220e' target=_blank style='color:#2F92EE;'>#一线治疗#</a> <a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a> <a href='/topic/show?id=c79411380f9' target=_blank style='color:#2F92EE;'>#MCL#</a>, objectTitle=【Blood】套细胞淋巴瘤一线治疗的现状和6个改善措施, objectType=article, longId=821416, objectId=1dfc8214160b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-staff-meeting-GXNVP9J.jpg, objectUrl=/article/show_article.do?id=1dfc8214160b, replyNumber=0, likeNumber=14, createdTime=2024-04-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=1dfc8214160b, moduleTitle=【Blood】套细胞淋巴瘤一线治疗的现状和6个改善措施, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1dfc8214160b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2193351, encodeId=714f2193351d7, content=<a href='/topic/show?id=9839112305ae' target=_blank style='color:#2F92EE;'>#吡托布鲁替尼#</a> <a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a> <a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=JCO：吡托布鲁替尼在先前共价BTK抑制剂治疗失败的套细胞淋巴瘤患者中显示出持久的疗效和良好的安全性, objectType=article, longId=817127, objectId=3e1881e127cd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240314/1710421976649_6145188.png, objectUrl=/article/show_article.do?id=3e1881e127cd, replyNumber=0, likeNumber=15, createdTime=2024-03-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3e1881e127cd, moduleTitle=JCO：吡托布鲁替尼在先前共价BTK抑制剂治疗失败的套细胞淋巴瘤患者中显示出持久的疗效和良好的安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e1881e127cd)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2190476, encodeId=066021904e608, content=<a href='/topic/show?id=81c2e4343a9' target=_blank style='color:#2F92EE;'>#神经毒性#</a> <a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a>, objectTitle=【Blood Adv】CAR-T治疗套细胞淋巴瘤的神经毒性的临床特征, objectType=article, longId=815380, objectId=12b9815380b0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301009/1696894910506_4754896.jpeg, objectUrl=/article/show_article.do?id=12b9815380b0, replyNumber=0, likeNumber=23, createdTime=2024-03-01, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=12b9815380b0, moduleTitle=【Blood Adv】CAR-T治疗套细胞淋巴瘤的神经毒性的临床特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12b9815380b0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2177183, encodeId=409b21e7183d5, content=<a href='/topic/show?id=970e659640a' target=_blank style='color:#2F92EE;'>#淋巴瘤#</a> <a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a> <a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=Eur J Cancer：243例继发性CNS淋巴瘤的真实世界治疗模式和结局：一项前瞻性观察性研究, objectType=article, longId=806838, objectId=361880683805, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20231220/c0c87d5265fc4672950f916d8ad11ab4.jpg, objectUrl=/article/show_article.do?id=361880683805, replyNumber=0, likeNumber=47, createdTime=2023-12-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=361880683805, moduleTitle=Eur J Cancer：243例继发性CNS淋巴瘤的真实世界治疗模式和结局：一项前瞻性观察性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=361880683805)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2176880, encodeId=c83721e6880fd, content=<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a> <a href='/topic/show?id=f92a8602447' target=_blank style='color:#2F92EE;'>#自体造血干细胞移植#</a>, objectTitle=【Lancet Haematol】辩论：对于R/R MCL，CAR-T还是异基因HSCT？, objectType=article, longId=806681, objectId=6bce8066814e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/conference-with-doctors-in-medical-aprons-PT29AAG.jpg, objectUrl=/article/show_article.do?id=6bce8066814e, replyNumber=0, likeNumber=33, createdTime=2023-12-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=6bce8066814e, moduleTitle=【Lancet Haematol】辩论：对于R/R MCL，CAR-T还是异基因HSCT？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bce8066814e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2165231, encodeId=8a8b2165231ef, content=<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a> , objectTitle=2023 BSH指南：套细胞淋巴瘤的诊断和管理, objectType=guider, longId=26809, objectId=9a8b41c003a1e005, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=9a8b41c003a1e005, replyNumber=0, likeNumber=37, createdTime=2023-10-27, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=9a8b41c003a1e005, moduleTitle=2023 BSH指南：套细胞淋巴瘤的诊断和管理, moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=9a8b41c003a1e005)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=2162740, encodeId=73d52162e40c9, content=<a href='/topic/show?id=18cb50594f2' target=_blank style='color:#2F92EE;'>#微小残留病#</a>灶可实时预测<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a>患者预后, objectTitle=Blood：微小残留病灶可实时预测套细胞淋巴瘤患者预后, objectType=article, longId=741861, objectId=27dee4186166, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202201006/1665044706008_2110107.JPG, objectUrl=/article/show_article.do?id=27dee4186166, replyNumber=0, likeNumber=21, createdTime=2023-10-14, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=27dee4186166, moduleTitle=Blood：微小残留病灶可实时预测套细胞淋巴瘤患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27dee4186166)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=2117709, encodeId=6605211e70902, content=<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a><a href='/topic/show?id=970e659640a' target=_blank style='color:#2F92EE;'>#淋巴瘤#</a>, objectTitle=《套细胞淋巴瘤诊断与治疗中国指南（2022年版）》解读, objectType=guider, longId=21937, objectId=7bf1f1c002929810, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=7bf1f1c002929810, replyNumber=0, likeNumber=61, createdTime=2023-03-05, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7bf1f1c002929810, moduleTitle=《套细胞淋巴瘤诊断与治疗中国指南（2022年版）》解读, moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=7bf1f1c002929810)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2111785, encodeId=55a72111e854f, content=<a href='/topic/show?id=f336e29134' target=_blank style='color:#2F92EE;'>#FDA#</a>加速批准非共价<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a><a href='/topic/show?id=4449105134e3' target=_blank style='color:#2F92EE;'>#pirtobrutinib#</a>上市，用于复发或难治性<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a></a>，相信适应症会快速扩展。百悦泽（<a href='/topic/show?id=2c90650e5b1' target=_blank style='color:#2F92EE;'>#泽布替尼#</a>）适应症包括既往至少接受过一种治疗的<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a></a>（MCL）、<a href='/topic/show?id=bde45355068' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞白血病#</a>/<a href='/topic/show?id=b0694e05245' target=_blank style='color:#2F92EE;'>#小淋巴细胞淋巴瘤#</a>（CLL/SLL）和<a href='/topic/show?id=391935910a2' target=_blank style='color:#2F92EE;'>#华氏巨球蛋白血症#</a>（WM）成人患者。, objectTitle=FDA加速批准非共价BTK抑制剂pirtobrutinib上市，用于复发或难治性套细胞淋巴瘤, objectType=article, longId=757311, objectId=4389e57311db, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20230111/95519c54e03e45a6a91941d7963d6271.jpg, objectUrl=/article/show_article.do?id=4389e57311db, replyNumber=0, likeNumber=88, createdTime=2023-01-28, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4389e57311db, moduleTitle=FDA加速批准非共价BTK抑制剂pirtobrutinib上市，用于复发或难治性套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4389e57311db)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1242688, encodeId=08411242688ca, content=<a href='/topic/show?id=2c90650e5b1' target=_blank style='color:#2F92EE;'>#泽布替尼#</a>治疗复发/难治性<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a>, objectTitle=Blood：泽布替尼治疗复发/难治性套细胞淋巴瘤的长期疗效, objectType=article, longId=301380, objectId=19cc301380e9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2022321/1647874982825_2467676.JPG, objectUrl=/article/show_article.do?id=19cc301380e9, replyNumber=0, likeNumber=67, createdTime=2022-09-02, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19cc301380e9, moduleTitle=Blood：泽布替尼治疗复发/难治性套细胞淋巴瘤的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19cc301380e9)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1220361, encodeId=7ff71220361e4, content=<a href='/topic/show?id=5be526941ee' target=_blank style='color:#2F92EE;'>#依鲁替尼#</a>联合<a href='/topic/show?id=820e3228e1b' target=_blank style='color:#2F92EE;'>#利妥昔单抗#</a>一线治疗<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a>, objectTitle=J Clin Oncol：依鲁替尼联合利妥昔单抗一线治疗套细胞淋巴瘤老年患者的疗效, objectType=article, longId=221135, objectId=393f22113570, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20211126/1637929373926_2110107.JPG, objectUrl=/article/show_article.do?id=393f22113570, replyNumber=0, likeNumber=94, createdTime=2022-05-17, rootId=0, userName=赛华佗, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=393f22113570, moduleTitle=J Clin Oncol：依鲁替尼联合利妥昔单抗一线治疗套细胞淋巴瘤老年患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=393f22113570)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1201329, encodeId=12db120132960, content=<a href='/topic/show?id=5be526941ee' target=_blank style='color:#2F92EE;'>#依鲁替尼#</a>-<a href='/topic/show?id=820e3228e1b' target=_blank style='color:#2F92EE;'>#利妥昔单抗#</a>诱导治疗可减少<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a>的化疗疗程, objectTitle=Lancet Oncol：依鲁替尼-利妥昔单抗诱导治疗可减少套细胞淋巴瘤的化疗疗程, objectType=article, longId=295064, objectId=3d5529506462, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202222/1643796790052_5552845.jpg, objectUrl=/article/show_article.do?id=3d5529506462, replyNumber=0, likeNumber=94, createdTime=2022-03-10, rootId=0, userName=医者仁者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d5529506462, moduleTitle=Lancet Oncol：依鲁替尼-利妥昔单抗诱导治疗可减少套细胞淋巴瘤的化疗疗程, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d5529506462)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=918820, encodeId=0e08918820a3, content=<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a>, objectTitle=Lancet Haematol：3期| 套细胞淋巴瘤自体造血干细胞移植后采用来那度胺维持治疗, objectType=article, longId=206002, objectId=eebf206002c2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/147963-medical-pills-capsules.jpg, objectUrl=/article/show_article.do?id=eebf206002c2, replyNumber=0, likeNumber=113, createdTime=2021-01-21, rootId=0, userName=zb1235672, userId=59321624668, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eebf206002c2, moduleTitle=Lancet Haematol：3期| 套细胞淋巴瘤自体造血干细胞移植后采用来那度胺维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eebf206002c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=904215, encodeId=fede9042159b, content=<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a>还是相当罕见的, objectTitle=Blood：依鲁替尼、Obinutuzumab和Venotclax联合治疗复发性/初治套细胞淋巴瘤, objectType=article, longId=204048, objectId=2fa5204048fb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020122/1606877914487_2110107.PNG, objectUrl=/article/show_article.do?id=2fa5204048fb, replyNumber=0, likeNumber=81, createdTime=2020-12-02, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fa5204048fb, moduleTitle=Blood：依鲁替尼、Obinutuzumab和Venotclax联合治疗复发性/初治套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fa5204048fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

套细胞淋巴瘤

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#一线治疗# #套细胞淋巴瘤# #MCL#

【Blood】套细胞淋巴瘤一线治疗的现状和6个改善措施

2024-04-14发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#吡托布鲁替尼# #套细胞淋巴瘤# #BTK抑制剂#

JCO：吡托布鲁替尼在先前共价BTK抑制剂治疗失败的套细胞淋巴瘤患者中显示出持久的疗效和良好的安全性

2024-03-15发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#神经毒性# #套细胞淋巴瘤# #CAR-T#

【Blood Adv】CAR-T治疗套细胞淋巴瘤的神经毒性的临床特征

2024-03-01发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#淋巴瘤# #套细胞淋巴瘤# #弥漫性大B细胞淋巴瘤#

Eur J Cancer：243例继发性CNS淋巴瘤的真实世界治疗模式和结局：一项前瞻性观察性研究

2023-12-26发表于威斯康星

梅斯管理员 (审核中...)

前往app查看评论内容

#套细胞淋巴瘤# #CAR-T# #自体造血干细胞移植#

【Lancet Haematol】辩论：对于R/R MCL，CAR-T还是异基因HSCT？

2023-12-24发表于上海

(审核中...)

前往app查看评论内容

#套细胞淋巴瘤#

2023 BSH指南：套细胞淋巴瘤的诊断和管理

2023-10-27发表于上海

(审核中...)

前往app查看评论内容

#微小残留病#灶可实时预测#套细胞淋巴瘤#患者预后

Blood：微小残留病灶可实时预测套细胞淋巴瘤患者预后

2023-10-14发表于上海

lifestar (审核中...)

前往app查看评论内容

#套细胞淋巴瘤##淋巴瘤#

《套细胞淋巴瘤诊断与治疗中国指南（2022年版）》解读

2023-03-05发表于上海

lifestar (审核中...)

前往app查看评论内容

全文收起 #FDA#加速批准非共价#BTK抑制剂##pirtobrutinib#上市，用于复发或难治性 #套细胞淋巴瘤#，相信适应症会快速扩展。百悦泽（#泽布替尼#）适应症包括既往至少接受过一种治疗的 #套细胞淋巴瘤#（MCL）、#慢性淋巴细胞白血病#/#小淋巴细胞淋巴瘤#（CLL/SLL）和#华氏巨球蛋白血症#（WM）成人患者。

FDA加速批准非共价BTK抑制剂pirtobrutinib上市，用于复发或难治性套细胞淋巴瘤

2023-01-28发表于上海

(审核中...)

前往app查看评论内容

#泽布替尼#治疗复发/难治性#套细胞淋巴瘤#

Blood：泽布替尼治疗复发/难治性套细胞淋巴瘤的长期疗效

2022-09-02

赛华佗 (审核中...)

前往app查看评论内容

#依鲁替尼#联合#利妥昔单抗#一线治疗#套细胞淋巴瘤#

J Clin Oncol：依鲁替尼联合利妥昔单抗一线治疗套细胞淋巴瘤老年患者的疗效

2022-05-17

医者仁者 (审核中...)

前往app查看评论内容

#依鲁替尼#-#利妥昔单抗#诱导治疗可减少#套细胞淋巴瘤#的化疗疗程

Lancet Oncol：依鲁替尼-利妥昔单抗诱导治疗可减少套细胞淋巴瘤的化疗疗程

2022-03-10

zb1235672 (审核中...)

前往app查看评论内容

#套细胞淋巴瘤#

Lancet Haematol：3期| 套细胞淋巴瘤自体造血干细胞移植后采用来那度胺维持治疗

2021-01-21

lovetcm (审核中...)

前往app查看评论内容

#套细胞淋巴瘤#还是相当罕见的

Blood：依鲁替尼、Obinutuzumab和Venotclax联合治疗复发性/初治套细胞淋巴瘤

2020-12-02

科室
- - 订阅+
  - 更多科室
工具
服务